 Secured strongest-ever balance sheet with approximately 33.1 million in cash Strengthened the Companys leadership team to drive commercial focus Expanded the Companys intellectual property portfolio Initiated production of product components at scale at the Companys Silver One facility Published three clinical papers Continued focus on product launches and licensing in both the human and veterinary spaces AUSTIN, Texas, May 11, 2021 PRNewswire -- VolitionRx Limited NYSE AMERICAN: VNRX Volition today announced financial results and a business update for the first quarter ended March 31, 2021. Volition management will host a conference call tomorrow, May 12 at 8:00 a.m. 